This article needs additional citations for verification. (April 2017) (Learn how and when to remove this template message)
A major contributor to this article appears to have a close connection with its subject. (April 2017) (Learn how and when to remove this template message)
Donald Jensen is an American hepatitis C researcher and clinician who works at Rush University Medical Center in Chicago. He attended high school in Springfield, IL, and was an undergraduate at the University of Illinois in Champaign-Urbana. He attained his MD degree from the University of Illinois in Chicago, and completed an internal medicine residency and chief medical resident at Rush University. He was subsequently a liver research fellow at King's College Hospital in London, UK, before returning to Rush as a faculty member. In 1999, he was appointed as the Richard B. Capps Professor of Medicine and chief of the section of hepatology. In 2005, he moved to the University of Chicago as professor of medicine and director of the Center for Liver Disease. In 2016, he assumed the position of Professor of Medicine at Rush University Medical Center.
In early 1990s he was a clinical investigator at Rush University who helped to develop a drug interferon for hepatitis C, and in 1998 assisted in the development of the combination of interferon and ribavirin for the treatment of chronic hepatitis C. In 2007, Dr. Jensen was featured as the Top Doc in Chicago Magazine. In May 2011, two new antiviral agents for which he performed investigations, have been released: telaprevir and boceprevir.
- "UCMC's Donald Jensen leads Chicago Magazine's parade of 'top doctors' - UChicago Medicine". www.uchospitals.edu. Retrieved 11 November 2017.
- Bonnie Miller Rubin (January 30, 2013). "Hepatitis C progress in pipeline". Chicago Tribune. Retrieved May 8, 2014.
|This biographical article related to medicine in the United States is a stub. You can help Wikipedia by expanding it.|